Galapagos/€GLPG

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Galapagos

Galapagos NV, abbreviated as GLPG on stock exchanges, is a global biotechnology firm specializing in the discovery and development of small molecule medicines. The company focuses on innovating treatments primarily in the fields of immunology and oncology. Founded in 1999, Galapagos operates out of its headquarters in Belgium and extends its reach across Europe and the United States, aiming to provide transformative therapies for significant unmet medical needs.

Ticker

€GLPG

Primary listing

AEX

Industry

Biotechnology
Headquarters

Employees

704

ISIN

BE0003818359

Galapagos Metrics

BasicAdvanced
€1.7B
-
-€2.57
-0.06
-

What the Analysts think about Galapagos

Analyst ratings (Buy, Hold, Sell) for Galapagos stock.

Bulls say / Bears say

Galapagos' strategic decision to spin off its innovative medicines unit by mid-2025 aims to provide clearer business prospects for investors, potentially enhancing shareholder value. (reuters.com)
The company's collaboration with Adaptimmune to develop TCR T-cell therapy candidate uza-cel for head & neck cancer, with potential milestone payments up to $465 million, signifies a strong commitment to expanding its oncology pipeline. (newsfilecorp.com)
Galapagos' partnership with BridGene Biosciences to develop a selective oral SMARCA2 PROTAC for precision oncology underscores its focus on innovative cancer treatments, with BridGene eligible for up to $159 million in payments. (stocktitan.net)
Multiple analysts have downgraded Galapagos' stock, with StockNews.com lowering its rating to 'sell' in April 2025, reflecting concerns about the company's financial outlook. (defenseworld.net)
The planned reorganization is expected to lead to the reduction of around 300 positions in Europe, or around 40% of the group's workforce, indicating potential operational challenges. (reuters.com)
Galapagos' stock has faced significant devaluation since late 2020, following the decision not to pursue FDA approval for its experimental rheumatoid arthritis treatment, raising concerns about its product pipeline. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Galapagos Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Galapagos Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €GLPG

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs